LOXL2 expression in stromal cells was significantly associated with tumor invasion depth, lymph node metastasis, lymphatic invasion, venous invasion, peritoneal dissemination, and survival in GC patients (Kasashima et al., 2014). This evidence concerns the gene LOXL2 and metastatic malignant neoplasm in the lymph nodes.